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Abstract 
Rationale/Objectives: Recent research suggests that not only does the use of 
recreational drugs impact working memory functioning, but more “everyday” aspects 
of memory (e.g. remembering to do something in the future) are also affected. 
Methods: Forty-three ecstasy-polydrug users and 51 non-ecstasy users were recruited 
from a university population. Each participant completed the Cognitive Failures 
Questionnaire (CFQ) and Everyday Memory Questionnaire (EMQ). Of these, 28 
ecstasy-polydrug users and 35 non-ecstasy users completed the Prospective Memory 
Questionnaire (PMQ). In addition, an objective measure of cognitive failures (the 
CFQ-for-others) was completed by friends of participants. Results: There was a main 
effect of ecstasy-polydrug use on CFQ, EMQ, CFQ-for-others, Long-Term (LT) PM 
and internally cued PM scores. These were slightly attenuated following control for 
working memory capacity. Correlations were found between the different indicators 
of everyday memory and various measures of illicit drug use. Cannabis featured 
prominently in this respect. In addition, all ecstasy-related deficits were reduced to 
below statistical significance following control for cannabis use. Conclusions:  The 
present study provides further support for cannabis related deficits in aspects of 
everyday memory functioning. Ecstasy may also be associated with cognitive slips, 
but not to the same extent as cannabis.    
 
Keywords: ecstasy, MDMA, cannabis, everyday memory, prospective memory, 
cognitive failure 
 
 
Introduction 
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With millions of individuals using the recreational drug ecstasy worldwide, 
the increasing amount of evidence reporting adverse effects of the drug is of major 
concern. Research suggests that ecstasy (MDMA) has adverse effects on human 
memory, but while there is substantial evidence of working memory impairments in 
users of ecstasy (e.g. Morgan, 1999, 2000; Parrot and Lasky, 1998; Wareing et al, 
2000, 2004), the investigation of the effects of ecstasy on more everyday aspects of 
memory is relatively neglected. Crucial aspects of everyday memory include 
prospective remembering (i.e. remembering to do a certain thing at a certain time in 
the future) and the occurrence of “cognitive slips” (e.g. slips of memory, language and 
attention).  
A number of laboratory studies have assessed self-reports of cognitive failures 
and prospective memory in ecstasy users. Heffernan et al (2001a) assessed 
Prospective memory in recreational drug users using the prospective memory 
questionnaire (Hannon et al. 1995). Ecstasy users reported more prospective memory 
errors on the subscales of short-term habitual prospective memory, long-term episodic 
prospective memory and internally cued memory than non-users in study one, 
although there were no group differences in strategies used to aid remembering. This 
was replicated for short-term habitual and long-term episodic prospective memory in 
study two of the same paper (Heffernan et al. 2001a), where ecstasy users also 
performed worse on an executive function task. It was concluded that prospective 
memory and executive function are linked, although the possible link was not directly 
investigated. The findings of study one were replicated by Heffernan et al (2001b), 
where ecstasy users reported more errors in short-term habitual, long-term episodic, 
and internally cued prospective memory (although the mean occasions of ecstasy use 
for this study was at least 10 times per month, which is atypically high). There were 
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no group differences in strategies used to remember. In a study on the World Wide 
Web, Rodgers et al (2001) assessed everyday memory and prospective memory in 
drug users. It was found that while cannabis use was associated with “here and now” 
memory deficits in short-term habitual and internally-cued prospective memory, 
ecstasy use was associated with long-term memory problems, that were more related 
to storage and retrieval problems. In a second World Wide Web study, Rodgers et al 
(2003) found that long-term prospective memory deficits were associated with ecstasy 
use, while deficits in everyday memory were associated with frequency of cannabis 
use. Thus it is possible that different recreational drugs affect human memory in 
distinct ways. Ecstasy users also reported a higher incidence of cognitive slips than 
nonusers (Fox et al, 2001), although this was not replicated by Rodgers (2000), and 
no differences between ecstasy users, cannabis users and nonusers were reported on 
the cognitive failures questionnaire by Heffernan et al (2001a).  
 Although the World Wide Web is an effective way of collecting large amounts 
of data, and Rodgers et al (2001, 2003) have managed to attribute specific deficits in 
everyday memory to specific drugs, it is possible that individuals visiting drug 
websites may already believe that they have a memory problem, and thus are not 
representative of the drug-using population as a whole. Therefore one aim of the 
present study was to assess prospective memory, everyday memory and cognitive 
failures in recreational ecstasy users in a controlled laboratory setting.  
 The lack of evidence on self-reported cognitive failures and the inconsistent 
results with reference to the three subscales of the prospective memory questionnaire 
could reflect a metacognitive deficit in ecstasy users, whereby they do not realise their 
cognitive slips. Heffernan et al (2005) attempted to control for this by using a self-
report and objective measure (video-based) prospective memory task. Ecstasy users 
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reported significantly more forgetting on the long-term prospective memory scale, 
and also recalled significantly fewer items on the video-based prospective memory 
task. However, Cohen (1996) argues that self-report questionnaires are assessed better 
by gaining an independent measure of everyday performance such as that provided by 
ratings by a third party. In the present study, this concern is addressed by the 
Cognitive Failures Questionnaire-for-others (CFQ-others), a questionnaire to be 
completed by individuals who have a significant relationship with the Cognitive 
Failure Questionnaire (CFQ) respondent. The CFQ-others provides a means of 
determining whether the self-reports of CFQ respondents are subjective, or whether 
their beliefs about their own cognitive failures are generally accurate. Broadbent et al. 
(1982) found that there was a good correlation between the judgements of CFQ 
respondents and CFQ-others respondents. The correlation suggests that individuals 
who report more cognitive slips do in fact produce more such errors. Thus the 
possibility of a metacognitive deficit in ecstasy users is investigated in the present 
study.  
 The suggested relationship between central executive and prospective memory 
functioning would be in line with the finding that performance of a concurrent central 
executive task impaired performance in a laboratory-based prospective memory task 
in non drug using participants (Marsh & Hicks, 1998). As noted above, ecstasy users 
exhibit deficits on a number of executive tasks, and consequently the deficits in 
prospective memory noted above could be due to reduced executive resources, rather 
than a specific prospective memory deficit. 
 To summarise, the present study aims to assess everyday memory via self-
reports of cognitive failures, prospective memory and everyday memory in a 
laboratory setting. In addition, an objective measure of cognitive failures will be 
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included (the CFQ-others). The differential effects of recreational drugs on aspects of 
everyday memory will also be investigated. As it has been suggested that there is a 
link between prospective remembering and executive function, the possible mediating 
effects of executive function on PM will also be investigated.  
 
Method 
Design: A multivariate design was used for the Everyday Memory Questionnaire 
(EMQ) and CFQ, with scores as the dependent variables. A univariate design was 
used for the CFQ-for-others and for the PM-strategies. A multivariate design was 
used for the PMQ, with the three subscales as the dependent measures (long-term 
episodic, short-term habitual, internally cued). In all analyses, ecstasy user/nonuser 
was the between participants variable. ANCOVA was used to assess the possible 
mediating effects of executive function (computation span, random letter generation), 
gender, strategies used to aid remembering and cannabis on everyday memory. Non-
parametric (Spearman’s) correlations were used to assess the relationship between 
drug use variables and dependent variables.  
Participants: Forty-three ecstasy-polydrug users (mean age 21.56; 24 male) 
and 51 nonusers (mean age 21.51; 17 male) completed the CFQ and EMQ. As the 
PMQ only became available to use after the start of data collection, only 28 ecstasy-
polydrug users and 35 nonusers completed the PMQ. Data collected on the CFQ-
others relied on the partners/families of participants returning the questionnaire; the 
partners/families of 26 ecstasy-polydrug users and 31 nonusers returned the 
questionnaires. Participants were recruited via direct approach to university students 
and the snowball technique (Solowij et al, 1992). Participants were requested to 
refrain from ecstasy use for at least 7 days and ideally 10 days prior to testing (mean 
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abstinence period 8.82 weeks, median abstinence period 2 weeks). Participants were 
also requested not to use any other illicit drugs for at least 24 hours and ideally for 7 
days prior to testing.  
Materials: Patterns of drug use and other relevant lifestyle variables were 
investigated via means of a background questionnaire. The questionnaire gauged the 
use of ecstasy and other drugs, as well as age, years of education, general health and 
other relevant lifestyle variables. In relation to other drugs, participants were asked a 
range of questions including frequency and duration of use, and the last time that they 
had used each drug. Participants were also questioned concerning their history of drug 
use, and using a technique employed by Montgomery et al. (2005), these data were 
used to estimate total lifetime use for each drug. Average weekly dose and the amount 
of each drug consumed within the previous 30 days were also assessed. Fluid 
intelligence was measured via Raven’s Progressive Matrices (Raven et al. 1998), and 
premorbid intelligence was assessed via the National Adult Reading Test (NART, 
Nelson, 1982).   
Sleep Quality: A screening questionnaire and the Epworth Sleepiness Scale 
(ESS, Johns, 1991) were used to investigate any group differences in sleep quality. 
The ESS is a measure of subjective daytime sleepiness and contains eight items, 
which a participant has to score on a scale of 0 (would never doze off in this situation) 
to 3 (high chance of dozing off in this situation). A total score of all eight items was 
used in the analysis, and a high score was indicative of increased subjective daytime 
sleepiness. The screening questionnaire contained a number of questions on sleep 
quality, e.g. hours per night.  
Cognitive Failures: The Cognitive Failures Questionnaire and the Cognitive 
Failures Questionnaire-for-others (Broadbent et al. 1982) were administered. The 25-
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item CFQ is argued to measure the relationship between attentional performance and 
general cognitive functioning. The questions relate to different aspects of cognitive 
functioning and failure, such as perceptual failures (e.g. do you fail to notice signposts 
on the road?), misdirected actions (e.g. do you bump into people?) and memory 
failures (e.g. do you forget what you came to the shops to buy?) within the last 6 
months. The term “cognitive failure” is an umbrella term to cover all three types of 
slip. Each questionnaire item required a number (0-4 inclusive) to be circled. Four 
corresponded to “very often” and 0 to “never” (25 items in total). The direction of 
scoring for the CFQ was unidirectional, since pilot studies by Broadbent et al. (1982) 
found that reversed wording on some items only confused the participants and there 
were no differences in a small sample using reversed wording. In the case of the CFQ-
for-others half of the items began with “very often” and half with “never” (8 items in 
total). In the original study, Broadbent et al. use family or partners of the participant, 
but due to the nature of student populations, “housemate” has been added to the list of 
significant others in the present study. Total scores and percentage of slips reported 
were calculated to enable comparison between the two measures.  
Everyday memory: The Everyday Memory Questionnaire (EMQ, Sunderland 
et al. 1983) is a valid and reliable self-report measure of memory lapses in everyday 
activities. It consists of 27 statements, and in each case, participants respond on a 9-
point scale ranging from “not at all in the last 6 months” to “more than once a day”. 
Statements include: “forgetting where you put something”; “finding a television story 
difficult to follow”; a total score for everyday memory is calculated by summing the 
responses to all items.  
Prospective memory: This was assessed using the Prospective Memory 
Questionnaire (PMQ), which is a reliable and valid self-report measure (Hannon et 
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al., 1995). The PMQ provides measures of three aspects of PM on a scale of 1-9 for 
each scale. Fourteen questions measure short-term habitual PM, e.g. “I forgot to turn 
my alarm clock off when I got up this morning”. Fourteen items measure long-term 
episodic PM, e.g. “I forgot to pass on a message to someone”. Ten questions measure 
internally cued PM, e.g. “I forgot what I wanted to say in the middle of a sentence”. 
In addition, 14 questions make up the “techniques to remember” scale, which 
provides a measure of the number of strategies used to aid remembering. Responses 
on the three PM scales range from 1 (little forgetting) to 9 (great deal of forgetting), 
and for the strategies scale from 1 (few strategies) to 9 (many strategies). For each of 
the 4 scales, a total score is calculated by summing the responses in each section, and 
dividing by the number of items in that section (14 for ST-habitual, LT-episodic and 
strategies, 10 for internally cued). Thus scores on all 4 scales ranged from 1-9 with 
high scores being indicative of much forgetting, and many strategies used to aid 
remembering.  
Computation Span. Computation span has been used extensively as an 
indicator of working memory functioning in the cognitive ageing literature (Fisk & 
Warr, 1996; Salthouse & Babcock, 1991) and it is similar to the operation span 
measure used by Miyake, et al (2000) in their investigation of executive processes. 
Participants were required to solve a number of arithmetic problems (e.g., 4+7 = ?) by 
circling one of three multiple-choice answers as each problem was presented. They 
were also required to simultaneously remember the second digit of each presented 
problem. At the end of each set of problems the second digits had to be recalled in the 
order in which they were presented. The number of arithmetic problems that the 
participant had to solve, while at the same time remembering each second digit, 
gradually increased as the test proceeded. For each of the first three trials only a single 
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problem was presented. For the next three trials, two problems were presented. 
Subsequently, the number of problems presented per trial increased by one every third 
trial. In order to proceed, the participant was required to be correct in at least two of 
the three trials at the current level. Computation span was defined as the maximum 
number of end digits recalled in serial order, with the added requirement that the 
corresponding arithmetic problems had been solved correctly. 
Random letter generation (Baddeley, 1996). A computer display and 
concurrent auditory signal was used to pace responses. Participants were asked to 
speak aloud a letter every time the signal was presented. They were told to avoid 
repeating the same sequence of letters, to avoid producing alphabetical sequences, and 
to try to speak each letter with the same overall frequency. Individuals attempted to 
produce three sets of 100 letters; one set at a rate of one letter every 4 s, a second set 
at one letter every 2 s, and a third at one letter every 1 s. The order in which the sets 
were generated was randomised. The experimenter recorded the responses on an 
answer sheet. The test yields four scores. First, the number of alphabetically ordered 
pairs; second, a repeat sequences score corresponding to the number of times that the 
same letter pair is repeated; third, a “redundancy” score, which measures the extent to 
which all 26 letters of the alphabet are produced equally often (0% being truly 
random); and fourth, the number of letters produced. In the first three cases, higher 
scores indicate poor performance; in the fourth the opposite is the case. The scores for 
each separate variable, at each of the three generation rates, were standardised. A 
single score for each random generation measure was produced by averaging the 
standardised scores for the three production rates. 
Procedure  
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Participants were informed of the general purpose of the experiment, and 
written informed consent was obtained. The tasks were administered under laboratory 
conditions, and a computer running MS-DOS was used for the computer based tasks. 
The tests were administered in the following order: background questionnaire, sleep 
quality questionnaires, NART, CFQ, EMQ, PMQ, random letter generation, 
computation span, and Raven’s progressive matrices. Participants were given the 
CFQ-for-others and asked to get someone that had a day-to-day experience with them 
to fill it in. The CFQ respondents were requested not to discuss the responses that they 
had made prior to completion of the CFQ-for-others. The CFQ-for-others was 
returned via post in a pre-paid envelope. Participants were fully debriefed, paid £15 in 
store vouchers, and given drugs education leaflets. The study was approved by the 
Ethics Committee of Liverpool John Moores University, and was administered in 
accordance with the ethical guidelines of the British Psychological Society. 
 
Results 
The scores for background measures are set out in Table 1. A series of t-tests 
revealed that there were no significant differences between the groups in age, self-
rated health, random letter generation, fluid intelligence, pre-morbid intelligence, 
years of education, subjective daytime sleepiness, or average hours of sleep per night. 
Ecstasy-polydrug users did however report consuming significantly more units of 
alcohol per week, t(76.99) = 3.60, p<.001 (as Levene’s test was significant, degrees of 
freedom have been adjusted accordingly). Ecstasy-polydrug users also attained a 
lower level on the computation span task, indicating reduced working memory 
capacity, t(92) = -3.45, p<.001.  
   <Insert Table 1 Here> 
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The scores for everyday memory measures are set out in Table 2.  
CFQ and EMQ: Table 2 shows that ecstasy-polydrug users scored higher than 
nonusers on the CFQ and EMQ, indicating a higher incidence of self-reported 
everyday memory and cognitive failure slips. There was a main effect of ecstasy-
polydrug use on these measures, F(2,88) = 4.61, p<.05 for Pillai’s Trace. Separate 
univariate analyses revealed that ecstasy-polydrug users scored significantly higher on 
both the EMQ and CFQ, F(1,89) = 9.02; 6.05, p<.01 and p<.05 respectively.  
CFQ-for-others: The relatives/significant others reported more cognitive slips among 
ecstasy-polydrug users than nonusers (means of 14.65 and 10.71 respectively). 
Univariate ANOVA revealed that this difference was significant, F(1,55) = 8.44, 
p<.01.   
PMQ: Table 2 shows that ecstasy-polydrug users scored slightly higher than nonusers 
on the four subscales of the PMQ. The three memory measures (long-term episodic, 
short-term habitual and internally cued prospective memory) were incorporated into 
MANOVA. The main effect of ecstasy-polydrug use was non-significant, F(3,59) = 
2.00, p>.05, as was the univariate ecstasy-related difference in short-term habitual 
PM, F(1,61) = 0.61, p>.05. Ecstasy-polydrug related deficits in long-term and 
internally cued PM were significant, F(1,61) = 3.32, p<.05 one-tailed, and F(1,61) = 
5.82, p<.05 respectively. Univariate ANOVA revealed that ecstasy users did not use 
significantly more strategies to remember than nonusers, F(1,61) = 1.35, p>.05.  
Interaction between CFQ and CFQ-for-others: To assess whether users’ own 
perceptions of cognitive failures were similar in magnitude to the equivalent 
judgements produced by others, the CFQ and CFQ-for-others responses were 
compared for users and nonusers. The percentage of slips reported for each scale was 
calculated and analysed using a mixed design, with one within participants factor for 
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“cognitive failures”, (with two levels, self-report versus others), and ecstasy-polydrug 
user group between participants. Mean percentages of self-reported slips and other-
reported slips were similar for each group (indicating that ecstasy users were self-
aware of their cognitive failures). This was supported by a main effect of ecstasy use, 
F(1,55) = 9.20, p<.01. The interaction between cognitive failures and having used 
ecstasy was however non-significant indicating that ecstasy users were aware of their 
cognitive slips F(1,55) = 1.36, p>.05.  
    <Insert Table 2 Here> 
Inspection of Table 3 reveals that while the use of other drugs among the 
ecstasy-polydrug users was commonplace, among the nonusers it was limited mainly 
to the use of cannabis. The ecstasy-polydrug users had a lifetime dose of cannabis 
more than three times that of the non-users (4088 joints to 1228 joints), in addition to 
using it more frequently (2.90 times a week, compared to 0.84 times a week), having 
smoked more in the last 30 days (48.25 joints compared to 8.26 joints), and having a 
larger average weekly dose (13.91 joints compared to 5.84 joints). In relation to the 
cannabis measures, t-test revealed that all of the group difference were statistically 
significant  t(36.75) = 2.74, p<.01 for total lifetime dose; t(39.21) = 3.93, p<.01 for 
frequency of use; t(30.93) = 2.80, p<.01 for amount used in the last 30 days; and 
t(45.89) = 2.14, p<.05 for average dose (As Levene’s test was significant, degrees of 
freedom have been adjusted accordingly).    
   <Insert Table 3 Here> 
Correlations with Indices of Drug Use. 
Due to the small number of illicit drug users among the non ecstasy-polydrug 
user group it was not possible to control statistically for the effects of drugs other than 
cannabis through the use of ANCOVA (see below). Therefore it is possible that some 
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or all of the ecstasy-related effects might have been attributable to the effects of other 
drugs. To address this possibility, correlations were performed with different 
measures of ecstasy, amphetamine, cannabis and cocaine use. Measures of lifetime 
use of each drug, the number of times each drug was consumed each week, the 
amount of each drug consumed within the last 30 days, and the average weekly dose 
(i.e. total amount consumed divided by the length of use in weeks)
 
were all included
1
. 
For each of these a value of zero was entered for nonusers of the drug in question. In 
addition, for each illicit drug, a categorical variable in which users and nonusers of 
each drug were coded as 0 or 1 respectively was included.  
A full Bonferroni correction is not appropriate in this case, as the performance 
measures are intercorrelated (Sankoh et al. 1997). However multiple comparisons 
remain potentially problematic, therefore an intermediate level of correction has been 
calculated using the procedure outlined by Sankoh et al. (1997). The results, set out in 
Table 4, show that ecstasy use was significantly correlated with a number of the 
performance measures. Having ever used ecstasy was significantly correlated with 
EMQ, CFQ, and CFQ-for-others scores, while total lifetime dose of ecstasy was 
significantly correlated with CFQ-for-others scores. Average weekly ecstasy dose was 
also significantly correlated with EMQ, CFQ and PM-internally cued scores.  
In relation to other drugs, cannabis appears to be an especially important 
predictor of everyday memory deficits. Indeed, being a cannabis user, total lifetime 
dose of cannabis, and average weekly dose of cannabis were significantly correlated 
with all measures of everyday memory (at p<.01). Frequency of cannabis use was 
significantly correlated with EMQ, CFQ, CFQ-for-others, PM-internally cued and 
PM-strategies scores, while amount used in the last 30 days was significantly 
correlated with PM-internally cued. Ever having used cocaine was significantly 
 15 
correlated with CFQ-for others and PM-internally cued scores. Indices of 
amphetamine use were also significantly correlated with memory scores; Ever having 
used amphetamine with CFQ, CFQ-for-others and PM-internally cued, total lifetime 
dose with CFQ and CFQ-for-others scores and average dose with CFQ scores.  
   <Insert Table 4 Here> 
 So to summarise, cannabis appears to be a more important predictor of 
everyday memory deficits than ecstasy use, although on one scale (the CFQ-for-
others) ecstasy emerged as a more significant predictor.  
   
Covariate Analyses 
 Units of alcohol consumed in a week and gender composition were 
significantly different between the groups, thus these were incorporated into 
ANCOVA to control for the contribution of these factors to memory deficits.  
EMQ and CFQ: After controlling for gender, the main effect of ecstasy use remained 
significant, F(2,87) = 5.07, p<.01, as did the univariate analyses, F(1,88) = 9.18; 8.05, 
p<.005 and p<.01 for EMQ and CFQ respectively. Following control for units of 
alcohol used in a week, the main effect of ecstasy use remained significant, F(2,85) = 
5.00, p<.01. Ecstasy-related differences in EMQ and CFQ scores were intensified 
after controlling for alcohol use, F(1,86) = 9.65; 6.95,  p<.01 in both cases.  
CFQ-for-others: After controlling for gender, the main effect of ecstasy use remained 
significant, F(1,54) = 8.23, p<.01, and also after control for units of alcohol consumed 
in a week, F(1,52) = 9.02, p<.01.  
PMQ: After controlling for gender, the main effect of ecstasy remained non-
significant, F(3,58) = 2.15, p>.05, as did differences in short-term PM (F<1). The 
ecstasy-related differences in long-term PM and Internally cued PM remained 
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significant after control for gender, F(1,60) = 3.26, p<.05 one tailed and F(1,60) = 
6.37, p<.05 respectively. After controlling for average units of alcohol consumed in a 
week, the main effect of ecstasy use remained non-significant, F(3,37) = 1.12, p>.05, 
as did differences in short-term PM (F<1). Ecstasy-related differences in long-term 
PM were reduced to below statistical significance after control for alcohol use. Again, 
although slightly attenuated the ecstasy-related differences in internally cued PM 
remained significant after control for alcohol use, F(1,59) = 3.31, p<.05 one-tailed.  
 As it was also possible that strategies used to remember may have mediated 
the number of prospective memory slips (more strategies used may decrease the 
number of slips), this was incorporated into ANCOVA. The main effect of ecstasy use 
remained non-significant, F(3,58) = 1.71, 0>.05, as did short-term PM (F<1). Ecstasy-
related differences in long-term PM were reduced to below statistical significance 
following control for strategies used to remember. After control for strategies used to 
remember, ecstasy-related differences in internally cued PM remained significant, 
F(1,60) = 5.08, p<.05.  
 Homogeneity of regression was obtained with respect to all covariates in this 
block, p>.05 for the group by covariate interaction.    
Everyday Memory and Executive Function 
 One aim of the study was to assess the possible mediating role of executive 
resources on deficits in prospective memory. Therefore, computation span and 
random letter generation were also controlled for.  
EMQ and CFQ:  After controlling for working memory capacity, the main effect of 
ecstasy use remained significant, F(2,83) = 2.99, p<.05 (one-tailed). Although slightly 
attenuated, the ecstasy-related deficits in EMQ and CFQ scores remained significant, 
F(1,84) = 5.91, p<.05 for EMQ; F(1,84) = 3.74, 0<.05 (one-tailed) for CFQ. 
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Homogeneity of regression was obtained, p>.05 for the group by covariate 
interaction.  
CFQ-for-others: The main effect of ecstasy use also remained significant after control 
for working memory capacity, F(1,50) = 6.62, p<.05. Homogeneity of regression was 
obtained with respect to random letter generation (p>.05 for the group by covariate 
interaction); the group by covariate interaction was however significant for 
computation span, F(1,50) = 9.09, p<.01, so this result should be treated with some 
caution.  
Prospective Memory: After controlling for working memory, the main effect of 
ecstasy remained non-significant, F(3,54) = 1.34, p>.05, as did differences in short-
term PM (F<1). The ecstasy-related differences in long-term PM were reduced to 
below statistical significance after control for working memory capacity. Although 
slightly attenuated, ecstasy-related differences in internally cued PM remained 
significant after control for working memory capacity, F(1,56) = 3.88, p<.05 one-
tailed. Homogeneity of regression was obtained with respect to these covariate, p>.05 
for the group by covariate interaction.  
 It is therefore apparent that working memory capacity is not an important 
mediator of everyday memory deficits in ecstasy-polydrug users and cannabis users.   
 Finally the analyses were re-run with cannabis use variables
1
 as covariates.  
EMQ and CFQ (28 ecstasy users, 16 nonusers):  After controlling for cannabis use, 
the main effect of ecstasy use was reduced to below statistical significance, F(2,37) = 
0.31, p>.05. Group differences in CFQ and EMQ were also reduced to below 
statistical significance, F(1,38) = 0.49, p>.05 for CFQ; F(1,38) = 0.51, p>.05 for CFQ. 
                                                 
1
 Average dose, amount consumed in the last 30 days, total lifetime dose, frequency of use.  
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Homogeneity of regression was obtained, p>.05 for the group by covariate 
interaction, with the exception of frequency of cannabis use on the CFQ.  
CFQ-for-others: The main effect of ecstasy use was reduced to below statistical 
significance following control for cannabis use, F(1,24) = 0.75, p>.05. Homogeneity 
of regression was obtained with respect to all covariates, p>.05 for the group by 
covariate interaction.  
Prospective Memory (19 ecstasy users, 13 nonusers): After controlling for cannabis 
the main effect of ecstasy remained non-significant, F(3,24) = 1.96, p>.05. The 
ecstasy-related differences in long-term PM and internally cued PM were reduced to 
below statistical significance after control for cannabis use (F<1). After control for 
cannabis use, group differences in ST PM were now statistically significant, F(1,26) = 
6.00, p<.05.  Homogeneity of regression was obtained with respect to these 
covariates, p>.05 for the group by covariate interaction. In summary, cannabis use 
appears to mediate group differences in everyday memory.  
 
DISCUSSION 
 Ecstasy-polydrug users scored significantly higher than nonusers on a number 
of everyday memory measures, and significantly lower on a working memory 
measure: the CFQ, EMQ, two subscales of the PMQ (long-term episodic and 
internally cued PM), and computation span. Ecstasy-polydrug users were also rated 
significantly higher by friends on the CFQ-for-others. The interaction between CFQ 
and CFQ-for-others scores and ecstasy-polydrug use was non-significant, indicating 
that ecstasy users do realise their cognitive slips. After controlling for gender, alcohol 
use, and working memory capacity, the ecstasy-polydrug related differences in ratings 
of cognitive failures, everyday memory and cognitive failures-for-others, and 
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internally cued prospective memory remained significant (although slightly attenuated 
after control for the last of these). Ecstasy-polydrug related differences in ratings of 
long-term PM were reduced to below statistical significance following control for 
working memory and alcohol use, although did remain significant after control for 
gender. The use of strategies to aid remembering on the PMQ reduced ecstasy-
polydrug related differences in LT-PM to below statistical significance, although 
differences in internally cued PM remained significant. Surprisingly, although there 
was a main effect of ecstasy use on most of the measures, in terms of the relative 
magnitudes of the correlations, cannabis use variables emerged as the most significant 
predictors of everyday memory scores, and ecstasy-polydrug differences were 
reduced to below statistical significance following control for indices of cannabis use.
 The findings of the present study provide some support for support for 
previous research. Firstly, we found that ecstasy-polydrug users rated themselves 
higher on the CFQ, indicating increased incidence of cognitive slips. This provides 
further support for Fox et al. (2001) who reported a higher incidence of cognitive slips 
in ecstasy users than in nonusers. However, Rodgers (2000) and Heffernan et al. 
(2001a) did not find any ecstasy-related differences on this version of the 
questionnaire. This may be due to differences in lifetime drug consumption. While 
both studies report that the ecstasy user group had used ecstasy 20 times over a 5-year 
period, Heffernan et al. (2001a) also report that the average dose was one tablet per 
session. As the average dose in the present study was 346.5 tablets, this raises the 
possible that the types of slip assessed by the cognitive failures questionnaire are 
relatively preserved until a certain threshold of ecstasy use is reached. However it is 
noteworthy that in previous research (e.g. Rodgers et al. 2001) there was a clear 
dissociation between cannabis-related and ecstasy-related everyday memory deficits. 
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In the present study deficits appear to be more attributable to cannabis use than 
ecstasy use.  
 Ecstasy users were also rated higher by friends on the CFQ-for-others. The 
percentages of reported slips for the CFQ and CFQ-for-others were relatively similar 
(45.42 and 45.79 for ecstasy users; 38.58 and 33.47 for nonusers). The interaction 
between ecstasy use and self- and other-reported slips was non-significant. It has been 
suggested that the absence of a deficit on this task in previous research may reflect a 
metacognitive deficit in ecstasy users, which renders them unable to monitor their 
cognitive state accurately. However, the results of the present study suggest that this 
group of ecstasy-polydrug users do realise their cognitive slips, which provides 
further support for Heffernan et al (2005) who found self-reported PM and objective 
PM slips in ecstasy users were similar. 
 Although ecstasy-polydrug users scored significantly higher on the EMQ 
indicating increased incidences of slips in everyday memory, cannabis use emerged as 
a more important predictor than ecstasy use. Similarly, Rodgers et al. (2003) found 
that frequency of cannabis use was the most important predictor of everyday memory 
scores.   
 Ecstasy-related differences were also observed on two sub-scales of the PMQ: 
long-term episodic PM and internally cued PM. This provides some support for 
Heffernan et al. (2001b) in which ecstasy users reported a greater number of 
prospective memory slips on the internally cued subscale than the long-term subscale, 
and also Heffernan et al. (2001a) who found evidence for prospective memory deficits 
in ecstasy users: Short-term, long-term and internally cued PM were all related to 
ecstasy use. Cannabis use was however a considerably more important predictor than 
ecstasy use in the present study with all group differences being reduced to below 
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statistical significance  following control for cannabis use variables, with the 
exception of ST PM.  Ecstasy-related group differences in ST PM became significant 
after control for cannabis use. It is likely that this reflects the decrease in the number 
of individuals in the analyses (indeed, the sample of nonusers was reduced by over 
half). In view of the non-significant outcome for all other prospective and everyday 
memory measures following ANCOVA, this should be treated with caution. On 
balance it appears that cannabis use is a more important predictor of everyday 
memory deficits.    
Control for working memory capacity slightly attenuated the everyday 
memory deficits (with the exception of LT-PM, which was reduced to below 
statistical significance). Heffernan et al. (2001a) suggested a link between executive 
functioning and prospective memory deficits in ecstasy users (as ecstasy users 
performed worse on both a word fluency task and PM task in their study), although 
they did not directly investigate such an interaction. The present study highlights the 
limited importance of working memory capacity as a mediator of differences in 
everyday memory in drug users. This may be compared with the situation among 
older adults, who perform worse on PM tasks partly due to decreased working 
memory capacity (e.g. Martin & Schuman-Hengsteler, 2001). In view of the 
differences noted there is little to suggest that the mechanisms underlying drug related 
deficits in everyday memory are the same as those underlying age-related deficits. 
 The focus of the present study was intended to be ecstasy use. There was a 
main effect of ecstasy use on most of the everyday memory measures, and indices of 
ecstasy use were associated with EMQ scores (ever used, average dose), CFQ scores 
(ever used, average dose), and CFQ-for-others scores (ever used, total lifetime dose). 
However, a number of other illicit drugs consumed by the participants tested here 
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appear to have produced effects on the measures that were administered. Indices of 
cannabis use seem to be particularly important predictors of everyday memory 
deficits. Indeed, having ever used cannabis, total lifetime dose and average weekly 
dose were significantly correlated with all everyday memory measures. Given that 40 
(maximum 43) of the ecstasy users and 26 (maximum 51) of the nonusers had ever 
tried cannabis, with 30 and 18 respectively being able to estimate lifetime 
consumption, it is entirely possible that the ecstasy-related group differences in 
ratings of everyday memory reflect some aspect of ecstasy-cannabis use, or cannabis 
only use (e.g. Schwartz et al. 1989). In fact, this is rather more likely given the 
relative magnitudes of the correlations. Studies which have attempted to adequately 
control for cannabis use via ANCOVA and regression analysis have found a 
dissociation between the two drugs in terms of their impact on aspects of everyday 
memory functioning: Rodgers et al. (2003) found that while cannabis use predicts 
self-reports of failures in everyday memory, long-term prospective memory deficits 
were related to ecstasy use. Rodgers et al. (2001) also found that cannabis use was 
related to self-reports of “here and now” (ST and internally cued PM) memory 
deficits, while ecstasy use was associated with long-term PM deficits. Heffernan et al. 
(2001a; 2001b) also found that ecstasy-related deficits in PM remained significant 
after control for alcohol, cannabis and cocaine, and a cannabis only group did not 
report more cognitive failures compared to ecstasy users and controls (2001a). The 
lifetime cannabis use of both the ecstasy-polydrug group, and the group who had ever 
used cannabis were both higher than for previous studies. It is therefore possible that 
the apparent cannabis effect on all measures (rather than just the short-term memory 
deficits as in previous studies) reflects the higher levels of consumption. To 
summarise, we concede that the ecstasy-polydrug related deficits in the present study 
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actually reflect some aspect of cannabis use, as suggested by Croft et al. (2001), 
although previous research suggests that some everyday memory deficits are related 
to ecstasy use. Some indices of cocaine (2 significant) and amphetamine (6 
significant) were also correlated with everyday memory measures.  However, the 
participants that these analyses were based were all ecstasy-polydrug users, so this 
should be treated with some caution.  
As with most studies in this area, there are a number of limitations. Due to the 
quasi-experimental design of the study, it is possible that the groups in each study 
may have differed on some variable other than ecstasy use. Some possibilities have 
been excluded such as intelligence (NART and Raven’s) and aspects of sleep quality. 
Clearly there were differences in the use of other illicit drugs. Group 
differences in other variables such as general health, nutrition, or some premorbid 
condition predating drug use (Verheul, 2001) cannot be ruled out. We obviously 
cannot guarantee the purity of the tablets consumed by the ecstasy users in the present 
study (Cole et al. 2002); though in a recent review of the literature, Parrot (2004) 
reports that analysis of the contents of ecstasy tablets from amnesty bins in nightclubs 
revealed that purity of tablets is approaching 100% MDMA.  All participants reported 
being ecstasy free for at least 7 days (mean abstinence period was 8.82 weeks, median 
abstinence period 2 weeks), and we have no reason to believe this information to be 
false (participants were not informed that they would be excluded prior to testing). 
The present study also relied on self-reports of memory slips. An objective measure of 
cognitive failures (the CFQ-for-others) suggests that the self-reports in the present 
study are accurate; this is likely to be the case for prospective memory deficits also 
(Heffernan et al. 2005).  
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To conclude, the present study sought to determine what the impact of 
ecstasy-polydrug use would be on aspects of everyday memory functioning. Ecstasy-
polydrug related deficits were observed on a prospective memory questionnaire, and a 
number of everyday cognitive slip questionnaires. Objective measures of cognitive 
failures suggest that ecstasy-polydrug users do realise their memory lapses. Cannabis 
use did however emerge as a more important predictor of everyday memory lapses 
than ecstasy use. Everyday memory lapses in drug users were mediated in part by 
reduced working memory capacity, although perhaps not to the same extent as in the 
cognitive ageing literature, so future research should also seek to investigate this 
relationship further.  
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Table 1 
Mean age, intelligence scores and other background variables 
 
 Ecstasy Users  Nonusers  
 Mean S.D. Mean S.D. 
Age 
 
21.56   1.68 21.51   1.79 
Units of Alcohol/week 
 
23.62 15.69 13.11 11.71 
Self-Rated Health 
 
  3.60   0.76   3.84   0.92 
Sleep (Hours/night) 
 
  8.02   1.47   7.99   1.32 
Epworth Sleepiness Scale Total 
 
  6.26   3.25   5.57   2.59 
Years of Education from Age 5 
 
15.95   1.57 15.94   1.76 
Raven’s Progressive Matrices Total 
 
48.84   5.93 48.22   5.30 
NART total 
 
28.95   6.91 30.27   5.74 
Computation Span 
 
  3.60   1.61   4.71   1.49 
Random Letter Generation 
 
  0.04   0.39  -0.03   0.45 
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Table 2 
Mean Scores on Everyday Memory Measures 
 
 
Ecstasy Users  Nonusers  
 
 
Mean S.D.  Mean S.D.  
Everyday Memory Questionnaire 
 
97.24 35.34 77.28 28.07 
Cognitive Failures Questionnaire 
 
46.95 15.28 39.68 12.93 
Cognitive Failures-Others 
 
14.65   6.44 10.71   3.63 
PM- Long-Term Episodic 
 
  3.06   1.52   2.52   0.76 
PM- Short-Term Habitual 
 
  1.26   0.32   1.19   0.32 
PM- Internally cued 
 
  2.92   1.25   2.30   0.76 
PM- Strategies 
 
  3.29   1.65   2.84   1.41 
CFQ-Percentage of Slips Reported 
 
45.42 16.66 38.58 10.29 
CFQ-others: Percentage of Slips Reported 
 
45.79 20.14 33.47 11.36 
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Table 3. 
 
Indicators of Drug Use Among Ecstasy Users and Non Ecstasy Users  
 
 
 Ecstasy 
Users 
  Non Ecstasy 
Users 
  
 Mean S.D. n Mean S.D. N 
Total Use       
   Ecstasy (Tablets)   346.50   379.32 43       - - - 
   Amphetamine (grams)     77.29   172.74 12       4 -   1 
   Cannabis (joints) 4087.89 5484.74 31 1277.76 1453.19 18 
   Cocaine (grams)     37.83     61.96 20       - - - 
       
Frequency of Use (times 
per week) 
      
   Ecstasy      0.45       0.38 41       - - - 
   Amphetamine      0.09       0.11  4       - - - 
   Cannabis      2.90       2.70 31       0.84       0.85 18 
   Cocaine      0.54       0.48 20       - - - 
       
Amount Used During  
Previous 30 Days 
      
   Ecstasy (tablets)      4.67       6.45 42       - - - 
   Amphetamine (grams)      1.20       2.68  5       - - - 
   Cannabis (joints)    48.25     77.02 30       8.26     10.65 17 
   Cocaine (grams)      2.54       2.38 18       - - - 
       
Average Weekly Dose       
   Ecstasy (tablets)      2.31       3.04 43       - - - 
   Amphetamine (grams)      0.39       0.54 10       1       0.09   1 
   Cannabis (joints)    13.91     16.08 30      5.84     10.03 18 
   Cocaine (grams)      0.34       0.43 20       - - - 
       
Number Ever Used       
   Amphetamine 21 - - 2 - - 
   Cannabis 40 - - 26 - - 
   Cocaine 34 - - 5 - - 
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Table 4 
Correlations With Indices of Drug Use 
 Ecstasy Cannabis Cocaine Amphetamine 
Ever Used     
EMQ -.283* -.328* -.165 -.159 
CFQ -.272* -.380* -.170 -.225* 
CFQ-others -.333* -.329* -.441* -.515* 
PM-LT episodic -.159 -.368* -.142 -.158 
PM-ST habitual -.111 -.394* -.190 -.186 
PM-internally cued -.276 -.465* -.307* -.323* 
PM-strategies -.130 -.479* -.013 -.076 
Total Lifetime Use     
EMQ  .242  .305*  .202  .214 
CFQ  .215  .361*  .158  .267* 
CFQ-others  .312*  .440*  .329  .389* 
PM-LT episodic  .116  .416*  .122  .201 
PM-ST habitual  .065  .366*  .304  .097 
PM-internally cued  .224  .515*  .258  .330 
PM-strategies  .053  .452* -.017  .072 
Use in Last 30 days     
EMQ  .139  .197  .061  .120 
CFQ  .034  .165  .015  .064 
CFQ-others  .105  .301  .044      - 
PM-LT episodic  .045  .213 -.051  .161 
PM-ST habitual  .004  .068  .034 -.116 
PM-internally cued  .153  .380*  .095  .077 
PM-strategies -.008  .208 -.169 -.154 
 
*    Correlation significant at p<.01, one-tailed 
   
 
                                                 
1
 Those in the nonuser group who reported that they had ever used amphetamine or cocaine (N= 2 and 
5 respectively) felt that they were unable to estimate their pattern of use accurately. 
